ago2014

http://www.citizen.org/Page.aspx?pid=532. Acceso 7 de febrero de
2014.
16. Ibid.
17. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas
2004(47):277-283.
18. Worst Pills, Best Pills, Drug Monograph: desogestrel and ethinyl
estradiol.
http://www.worstpills.org/member/drugprofile.cfm?m_id=30.
Acceso 7 de febrero de 2014.
19. Center for Drug Evaluation and Research. Medical Review for
Nuvaring, Part 1. 6 de octubre de 2000.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-
187_Nuvaring_medr_P1.pdf.
20. Siddiqui S. Side effects may include death: the story of the biggest
advance in birth control since the pill. Huffington Post. 18 de
diciembre de 2013.
http://www.huffingtonpost.com/2013/12/18/Nuvaring-bloodclots_n_4461429.html.
Acceso 10 de febrero de 2014.
21. Nuvaring Original Drug Label.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21187lbl
.pdf. Acceso 10 de febrero de 2014.
22. Vanity Fair. Why is potentially lethal contraceptive Nuvaring still on
the market? 9 de diciembre de 2013.
http://www.vanityfair.com/politics/2014/01/Nuvaring-lethalcontraceptive-trial.
Acceso 7 de febrero de 2014.
23. Center for Drug Evaluation and Research. Medical Review for
Nuvaring, Part 2.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-
187_Nuvaring_medr_P2.pdf. Acceso 11 de febrero de 2014.
24. Siddiqui S. Side effects may include death: the story of the biggest
advance in birth control since the pill. Huffington Post. 18 de
diciembre de 2013.
http://www.huffingtonpost.com/2013/12/18/Nuvaring-bloodclots_n_4461429.html.
Acceso 10 de febrero de 2014.
25. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous
thrombosis in users of non-oral hormonal contraception: follow-up
study, Denmark 2001-10. BMJ 2012;344:e2990.
26. Roumen FJ, Mishell DR. The contraceptive vaginal ring, Nuvaring,
a decade after its introduction. Eur J Contracept Reprod. Health
Care. 2012;17:415-427.
27. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous
thrombosis in users of non-oral hormonal contraception: follow-up
study, Denmark 2001-10. BMJ 2012;344:e2990.
28. Sidney, S (primary author). Combined hormonal contraceptives
(CHCs) and the risk of cardiovascular endpoints.
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.
Acceso 10 de febrero de 2014.
29. Ibid.
30. Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated
with the use of an etonogestrel-containing vaginal ring. Obstet
Gynecol 2013;122:800-8.
31. Nuvaring Label.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021187s
021lbl.pdf. Acceso 10 de febrero de 2014.
32. Sidney, S (primary author). Combined hormonal contraceptives
(CHCs) and the risk of cardiovascular endpoints.
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.
Acceso 10 de febrero de 2014.
Boletín Fármacos 2014; 17 (4)
33. Nuvaring Label.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021187s
021lbl.pdf. Acceso 10 de febrero de 2014.
34. Nuvaring Drug Label (Canadian).
http://www.merck.ca/assets/en/pdf/products/Nuvaring-PM_E.pdf.
Acceso 11 de febrero de 2014.
35. Nuvaring website. http://www.Nuvaring.com/Consumer/index.asp.
36. Food and Drug Administration. Pharmacology Review: NDA 21-
187. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-
187_Nuvaring_pharmr.pdf.
37. Nuvaring Label.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021187s
021lbl.pdf. Acceso 10 de febrero de 2014.
38. Nuvaring Label.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021187s
021lbl.pdf. Acceso 7 de febrero de 2014.
39. Roumen FJ, Mishell DR. The contraceptive vaginal ring, Nuvaring,
a decade after its introduction. Eur. J. Contracept. Reprod. Health
Care 2012;17:415-427.
40. Centers for Disease Control. Effectiveness of Family Planning
Methods.
http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/PDF/
Contraceptive_methods_508.pdf.
41. Burke A. The state of hormonal contraception today: benefits and
risks of hormonal contraceptives: progestin-only contraceptives. Am
J Obstet and Gynecol. 2011 Oct;205(4 Suppl):S14-7.
42. Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous
thromboembolic events in women taking progestin-only
contraception: a meta-analysis. BMJ 2012;345:e4944.
43. NexPlanon Drug
Label.http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/02
1529s010lbl.pdf
44. Mayo Clinic. Ectopic Pregnancy: Complications.
http://www.mayoclinic.org/diseases-conditions/ectopicpregnancy/basics/complications/con-20024262.
45. Centers for Disease Control. Contraception.
http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/Contr
aception.htm.
46. Centers for Disease Control. Effectiveness of Family Planning
Methods.
http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/PDF/
Contraceptive_methods_508.pdf. Acceso 11 de febrero de 2014.
47. Centers for Disease Control. Contraception.
http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/Contr
aception.htm.
48. Cornforth T. FDA approves mirana IUD. 19 de julio de 2009.
http://womenshealth.about.com/cs/iuds/a/fdaapprvmirena.htm.
Acceso 10 de febrero de 2014.
49. Association of Reproductive Health Professionals. The single-rod
contraceptive implant. Julio de 2008.
http://www.arhp.org/publications-and-resources/clinicalproceedings/Single-Rod/History.
Acceso 10 de febrero de 2014.
50. NexPlanon Drug
Label.http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/02
1529s010lbl.pdf
51. Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of
long-acting reversible contraception. Drugs 2011;71(8):969-980.
52. Nuvaring Drug Label (Canadian).
http://www.merck.ca/assets/en/pdf/products/Nuvaring-PM_E.pdf.
Acceso 11 de febrero de 2014.
Durante estos últimos meses se han publicado una serie de
artículos sobre el consumo de antibióticos en la infancia
El asma infantil y los antibióticos
Salud y Fármacos
22